Search

Willmon Fridie Jr.

Examiner (ID: 2181)

Most Active Art Unit
3722
Art Unit(s)
3206, 3203, 3727, 2899, 3204, 3724, 3722, 3721
Total Applications
3502
Issued Applications
3019
Pending Applications
114
Abandoned Applications
374

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 5545378 [patent_doc_number] => 20090155255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-06-18 [patent_title] => 'CD23 BINDING MOLECULES AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/240880 [patent_app_country] => US [patent_app_date] => 2008-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 49628 [patent_no_of_claims] => 72 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0155/20090155255.pdf [firstpage_image] =>[orig_patent_app_number] => 12240880 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/240880
CD23 BINDING MOLECULES AND METHODS OF USE THEREOF Sep 28, 2008 Abandoned
Array ( [id] => 5429099 [patent_doc_number] => 20090088409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-04-02 [patent_title] => 'SERUM BIOMARKERS FOR EARLY DETECTION OF ACUTE CELLULAR REJECTION' [patent_app_type] => utility [patent_app_number] => 12/235292 [patent_app_country] => US [patent_app_date] => 2008-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11975 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0088/20090088409.pdf [firstpage_image] =>[orig_patent_app_number] => 12235292 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/235292
Serum biomarkers for early detection of acute cellular rejection Sep 21, 2008 Issued
Array ( [id] => 15054861 [patent_doc_number] => 10457719 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof [patent_app_type] => utility [patent_app_number] => 12/678494 [patent_app_country] => US [patent_app_date] => 2008-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 21978 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 202 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12678494 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/678494
Antibodies and FC fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof Sep 16, 2008 Issued
Array ( [id] => 6292681 [patent_doc_number] => 20100239596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-23 [patent_title] => 'GRP78 AND TUMOR ANGIOGENESIS' [patent_app_type] => utility [patent_app_number] => 12/674583 [patent_app_country] => US [patent_app_date] => 2008-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 12388 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0239/20100239596.pdf [firstpage_image] =>[orig_patent_app_number] => 12674583 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/674583
GRP78 AND TUMOR ANGIOGENESIS Aug 21, 2008 Abandoned
Array ( [id] => 5367160 [patent_doc_number] => 20090304719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-12-10 [patent_title] => 'ACTIVATABLE BINDING POLYPEPTIDES AND METHODS OF IDENTIFICATION AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 12/196269 [patent_app_country] => US [patent_app_date] => 2008-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 40524 [patent_no_of_claims] => 144 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0304/20090304719.pdf [firstpage_image] =>[orig_patent_app_number] => 12196269 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/196269
ACTIVATABLE BINDING POLYPEPTIDES AND METHODS OF IDENTIFICATION AND USE THEREOF Aug 20, 2008 Abandoned
Array ( [id] => 5421947 [patent_doc_number] => 20090148402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-06-11 [patent_title] => 'THERAPY OF NON-MALIGNANT DISEASES OR DISORDERS WITH ANTI-ERBB2 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 12/193582 [patent_app_country] => US [patent_app_date] => 2008-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 31747 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0148/20090148402.pdf [firstpage_image] =>[orig_patent_app_number] => 12193582 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/193582
THERAPY OF NON-MALIGNANT DISEASES OR DISORDERS WITH ANTI-ERBB2 ANTIBODIES Aug 17, 2008 Abandoned
Array ( [id] => 5527774 [patent_doc_number] => 20090197851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-08-06 [patent_title] => 'THERAPY AND USE OF COMPOUNDS IN THERAPY' [patent_app_type] => utility [patent_app_number] => 12/187169 [patent_app_country] => US [patent_app_date] => 2008-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 20292 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0197/20090197851.pdf [firstpage_image] =>[orig_patent_app_number] => 12187169 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/187169
THERAPY AND USE OF COMPOUNDS IN THERAPY Aug 5, 2008 Abandoned
Array ( [id] => 6228778 [patent_doc_number] => 20100183516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-22 [patent_title] => 'SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 12/670565 [patent_app_country] => US [patent_app_date] => 2008-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 109 [patent_figures_cnt] => 109 [patent_no_of_words] => 30979 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12670565 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/670565
SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS Jul 24, 2008 Abandoned
Array ( [id] => 6504234 [patent_doc_number] => 20100260765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-14 [patent_title] => 'TARGETED BINDING AGENTS DIRECTED TO KDR AND USES THEREOF - 035' [patent_app_type] => utility [patent_app_number] => 12/669724 [patent_app_country] => US [patent_app_date] => 2008-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 61673 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0260/20100260765.pdf [firstpage_image] =>[orig_patent_app_number] => 12669724 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/669724
Targeted binding agents directed to KDR and uses thereof—035 Jul 22, 2008 Issued
Array ( [id] => 6528948 [patent_doc_number] => 20100015158 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-01-21 [patent_title] => 'METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION' [patent_app_type] => utility [patent_app_number] => 12/176238 [patent_app_country] => US [patent_app_date] => 2008-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11914 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0015/20100015158.pdf [firstpage_image] =>[orig_patent_app_number] => 12176238 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/176238
Method for treating atrophic age related macular degeneration Jul 17, 2008 Issued
Array ( [id] => 6468542 [patent_doc_number] => 20100190957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-29 [patent_title] => 'SPECIFIC THERAPY AND MEDICAMENT USING INTEGRIN LIGANDS FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 12/668823 [patent_app_country] => US [patent_app_date] => 2008-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 57703 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 36 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0190/20100190957.pdf [firstpage_image] =>[orig_patent_app_number] => 12668823 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/668823
SPECIFIC THERAPY AND MEDICAMENT USING INTEGRIN LIGANDS FOR TREATING CANCER Jul 16, 2008 Abandoned
Array ( [id] => 4560935 [patent_doc_number] => 07846437 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-12-07 [patent_title] => 'Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same' [patent_app_type] => utility [patent_app_number] => 12/165446 [patent_app_country] => US [patent_app_date] => 2008-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 5 [patent_no_of_words] => 26535 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/846/07846437.pdf [firstpage_image] =>[orig_patent_app_number] => 12165446 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/165446
Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same Jun 29, 2008 Issued
Array ( [id] => 288816 [patent_doc_number] => 07547440 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2009-06-16 [patent_title] => 'T-cell epitope peptides' [patent_app_type] => utility [patent_app_number] => 12/163896 [patent_app_country] => US [patent_app_date] => 2008-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5595 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 286 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/547/07547440.pdf [firstpage_image] =>[orig_patent_app_number] => 12163896 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/163896
T-cell epitope peptides Jun 26, 2008 Issued
Array ( [id] => 122087 [patent_doc_number] => 07704498 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2010-04-27 [patent_title] => 'ErbB4 antagonists' [patent_app_type] => utility [patent_app_number] => 12/215200 [patent_app_country] => US [patent_app_date] => 2008-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 29371 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/704/07704498.pdf [firstpage_image] =>[orig_patent_app_number] => 12215200 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/215200
ErbB4 antagonists Jun 23, 2008 Issued
Array ( [id] => 6601467 [patent_doc_number] => 20100322939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-23 [patent_title] => 'NOVEL METHODS FOR TREATING EGFR-ASSOCIATED TUMORS' [patent_app_type] => utility [patent_app_number] => 12/664258 [patent_app_country] => US [patent_app_date] => 2008-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10536 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0322/20100322939.pdf [firstpage_image] =>[orig_patent_app_number] => 12664258 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/664258
NOVEL METHODS FOR TREATING EGFR-ASSOCIATED TUMORS Jun 16, 2008 Abandoned
Array ( [id] => 5264443 [patent_doc_number] => 20090117128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-05-07 [patent_title] => 'Anti-HPA' [patent_app_type] => utility [patent_app_number] => 12/139086 [patent_app_country] => US [patent_app_date] => 2008-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5821 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0117/20090117128.pdf [firstpage_image] =>[orig_patent_app_number] => 12139086 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/139086
Anti-HPA Jun 12, 2008 Issued
Array ( [id] => 5309730 [patent_doc_number] => 20090017011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-01-15 [patent_title] => 'MODULATION OF VEGF-C/VEGFR-3 INTERACTIONS IN THE TREATMENT OF RHEUMATOID ARTHRITIS' [patent_app_type] => utility [patent_app_number] => 12/139102 [patent_app_country] => US [patent_app_date] => 2008-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17585 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0017/20090017011.pdf [firstpage_image] =>[orig_patent_app_number] => 12139102 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/139102
MODULATION OF VEGF-C/VEGFR-3 INTERACTIONS IN THE TREATMENT OF RHEUMATOID ARTHRITIS Jun 12, 2008 Abandoned
Array ( [id] => 4634025 [patent_doc_number] => 08012473 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-09-06 [patent_title] => 'C3b antibodies and methods for the prevention and treatment of complement-associated disorders' [patent_app_type] => utility [patent_app_number] => 12/157073 [patent_app_country] => US [patent_app_date] => 2008-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 19 [patent_no_of_words] => 27282 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/012/08012473.pdf [firstpage_image] =>[orig_patent_app_number] => 12157073 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/157073
C3b antibodies and methods for the prevention and treatment of complement-associated disorders Jun 5, 2008 Issued
Array ( [id] => 6270795 [patent_doc_number] => 20100254995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-07 [patent_title] => 'POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 12/663501 [patent_app_country] => US [patent_app_date] => 2008-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 91 [patent_figures_cnt] => 91 [patent_no_of_words] => 54927 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0254/20100254995.pdf [firstpage_image] =>[orig_patent_app_number] => 12663501 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/663501
POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS Jun 2, 2008 Abandoned
Array ( [id] => 6581695 [patent_doc_number] => 20100291103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-18 [patent_title] => 'POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 12/663505 [patent_app_country] => US [patent_app_date] => 2008-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 91 [patent_figures_cnt] => 91 [patent_no_of_words] => 53505 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0291/20100291103.pdf [firstpage_image] =>[orig_patent_app_number] => 12663505 [rel_patent_id] =>[rel_patent_doc_number] =>)
12/663505
Polypeptides, antibody variable domains and antagonists Jun 2, 2008 Issued
Menu